Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2337/dbi20-0045 http://scihub22266oqcxt.onion/10.2337/dbi20-0045 33632743!8173800!33632743     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Diabetes 2021 ; 70 (5): 1021-1028 Nephropedia Template TP {{tp|p=33632743|t=2021. How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic?|pdf=|usr=}}{{33632743}} gab.com Text How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic JO: Diabetes http://www.kidney.de/pget.php?&tw=1&pmid=33632743 #FOAvip Research-based immunotherapy trials seeking to prevent or reverse a number of autoimmune diseases, including type 1 diabetes, have seen near universal suspension due to the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diabetes and hyperglycemia are now appreciated as significant risk factors for COVID-19 morbidity and mortality; however, the vast majority of studies have reported on adults. Recent data in children and adolescents with type 1 diabetes suggest no increased risk of COVID-19. Even with immense appreciation for COVID-19 morbidity and mortality, we believe compelling arguments exist to carefully and thoughtfully resume certain type 1 diabetes phase 2-3 immunotherapy trials. In this Perspective, we consider the experience of trials that never halted or have resumed in the oncology and rheumatology fields, and advocate for staged type 1 diabetes immunotherapy trial resumption. With this, we present recommendations to achieve equipoise and mitigate risks for SARS-CoV-2 infection in the weeks surrounding infusion. Given the fact that the COVID-19 pandemic is expected to persist for some time, it is in the best interest of our patients that we find ways to safely move our field forward. Twit Text FOAVip How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic ????Diabetes http://www.kidney.de/pget.php?&tw=1&pmid=33632743 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33632743 #FOAvip English Wikipedia <ref>{{Cite pmid|33632743}}</ref> How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic? #MMPMID33632743 Haller MJ; Jacobsen LM; Posgai AL; Schatz DA Diabetes 2021[May]; 70 (5): 1021-1028 PMID33632743show ga Research-based immunotherapy trials seeking to prevent or reverse a number of autoimmune diseases, including type 1 diabetes, have seen near universal suspension due to the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diabetes and hyperglycemia are now appreciated as significant risk factors for COVID-19 morbidity and mortality; however, the vast majority of studies have reported on adults. Recent data in children and adolescents with type 1 diabetes suggest no increased risk of COVID-19. Even with immense appreciation for COVID-19 morbidity and mortality, we believe compelling arguments exist to carefully and thoughtfully resume certain type 1 diabetes phase 2-3 immunotherapy trials. In this Perspective, we consider the experience of trials that never halted or have resumed in the oncology and rheumatology fields, and advocate for staged type 1 diabetes immunotherapy trial resumption. With this, we present recommendations to achieve equipoise and mitigate risks for SARS-CoV-2 infection in the weeks surrounding infusion. Given the fact that the COVID-19 pandemic is expected to persist for some time, it is in the best interest of our patients that we find ways to safely move our field forward. |Antibodies, Monoclonal, Humanized/therapeutic use[MESH] |Antibodies, Monoclonal/therapeutic use[MESH] |COVID-19/epidemiology/mortality/*prevention & control[MESH] |Clinical Trials, Phase II as Topic[MESH] |Clinical Trials, Phase III as Topic[MESH] |Diabetes Mellitus, Type 1/*drug therapy[MESH] |Disease Progression[MESH] |Humans[MESH] |Immunosuppressive Agents/*therapeutic use[MESH] |Immunotherapy[MESH] |Inflammatory Bowel Diseases/drug therapy[MESH] |Leukemia/drug therapy[MESH] |Risk Assessment[MESH] |SARS-CoV-2[MESH]How Do We Move Type 1 Diabetes Immunotherapies Forward During the Curr(epmc).pdf DeepDyve Pubget Overpricing